Von Willebrand Disease in the Pediatric and Adolescent Population

Journal of Pediatric and Adolescent Gynecology

Volumn 23, Issue SUPPL. 6, 2010, Pages

  Mikhail, Sameh ^a   Kouides, Peter ^b  

^a GEORGETOWN UNIVERSITY HOSPITAL   (United States)

^b ROCHESTER GENERAL HOSPITAL   (United States)

Author keywords

Adolescents; Bleeding disorders; Bleeding score; Menorrhagia; Von Willebrand disease

Indexed keywords

ALPHANATE SD; AMINOCAPROIC ACID; ANTIFIBRINOLYTIC AGENT; BLOOD CLOTTING FACTOR 8 CONCENTRATE; DESMOPRESSIN; DESMOPRESSIN ACETATE; LEVONORGESTREL; TRANEXAMIC ACID; UNCLASSIFIED DRUG; WILLATE; ARGIPRESSIN[1 DEAMINO]; DIAGNOSTIC AGENT; HEMOSTATIC AGENT; VON WILLEBRAND FACTOR;

ACUTE HEART INFARCTION; ANAPHYLAXIS; ARTERY THROMBOSIS; ARTICLE; BLEEDING; CLINICAL FEATURE; COLOR VISION DEFECT; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED DISEASE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; EMBOLISM; EPISTAXIS; FLUID RETENTION; FLUSHING; HEART PALPITATION; HUMAN; HYPONATREMIA; HYPOTENSION; MEDICAL HISTORY; MENORRHAGIA; MOOD CHANGE; MUSCLE TENDERNESS; MYALGIA; OCCLUSIVE CEREBROVASCULAR DISEASE; ORAL CONTRACEPTION; ORTHOSTATIC HYPERTENSION; POSTPARTUM HEMORRHAGE; PREVALENCE; PRIORITY JOURNAL; QUESTIONNAIRE; SEIZURE; SIDE EFFECT; SMOKING; THROMBOCYTE TRANSFUSION; THROMBOSIS; TRANSIENT ISCHEMIC ATTACK; VEIN THROMBOSIS; VON WILLEBRAND DISEASE; ADOLESCENT; ANAMNESIS; CHILD; CONTUSION; FEMALE;

6-AMINOCAPROIC ACID; ADOLESCENT; ANTIFIBRINOLYTIC AGENTS; CHILD; CONTUSIONS; DEAMINO ARGININE VASOPRESSIN; EPISTAXIS; FEMALE; HEMOSTATICS; HUMANS; MEDICAL HISTORY TAKING; MENORRHAGIA; PLATELET TRANSFUSION; PREVALENCE; QUESTIONNAIRES; TRANEXAMIC ACID; VON WILLEBRAND DISEASES; VON WILLEBRAND FACTOR;

EID: 79952276294     PISSN: 10833188     EISSN: 18734332     Source Type: Journal    
DOI: 10.1016/j.jpag.2010.08.005     Document Type: Article

References (81)

1. Von Willebrand E.A. Hereditar pseudohemofili. Fin Lakarsallsk Handl 1926, 67:87.
2. Robertson J., Lillicrap D., James P.D. Von Willebrand disease. Pediatr Clin North Am 2008, 55:377.
3. Kadir R.A., Economides D.L., Sabin C.A., et al. Frequency of inherited bleeding disorders in women with menorrhagia. Lancet 1998, 351(9101):485.
4. Dilley A., Drews C., Miller C., et al. von Willebrand disease and other inherited bleeding disorders in women with diagnosed menorrhagia. Obstet Gynecol 2001, 97:630.
5. Woo Y.L., White B., Corbally R., et al. von Willebrand's disease: an important cause of dysfunctional uterine bleeding. Blood Coagul Fibrinolysis 2002, 13:89.
6. Edlund M., Blomback M., von Schoultz B., et al. On the value of menorrhagia as a predictor for coagulation disorders. Am J Hematol 1996, 53:234.
7. Philipp C.S., Dilley A., Miller C.H., et al. Platelet functional defects in women with unexplained menorrhagia. J Thromb Haemost 2003, 1:477.
8. Kouides P.A., Phatak P.D., Burkart P., et al. Gynaecological and obstetrical morbidity in women with type I von Willebrand disease: results of a patient survey. Haemophilia 2000, 6:643.
9. Ragni M.V., Bontempo F.A., Hassett A.C. von Willebrand disease and bleeding in women. Haemophilia 1999, 5:313.
10. Kirtava A., Drews C., Lally C., et al. Medical, reproductive and psychosocial experiences of women diagnosed with von Willebrand's disease receiving care in haemophilia treatment centres: a case-control study. Haemophilia 2003, 9:292.
11. Rodeghiero F., Castaman G., Dini E. Epidemiological investigation of the prevalence of von Willebrand's disease. Blood 1987, 69:454.
12. Bowman M., Hopman W.M., Rapson D., et al. The prevalence of symptomatic von Willebrand disease in primary care practice. J Thromb Haemost 2010, 8:213.
13. Bowman M., Hopman W.M., Rapson D., et al. A prospective evaluation of the prevalence of symptomatic von Willebrand disease (VWD) in a pediatric primary care population. Pediatr Blood Cancer 2010, 55:171.
14. Bevan J.A., Maloney K.W., Hillery C.A., et al. Bleeding disorders: A common cause of menorrhagia in adolescents. J Pediatr 2001, 138:856.
15. Claessens E.A., Cowell C.A. Acute adolescent menorrhagia. Am J Obstet Gynecol 1981, 139:277.
16. Falcone T., Desjardins C., Bourque J., et al. Dysfunctional uterine bleeding in adolescents. J Reprod Med 1994, 39:761.
17. Jayasinghe Y., Moore P., Donath S., et al. Bleeding disorders in teenagers presenting with menorrhagia. Aust N Z J Obstet Gynaecol 2005, 45:439.
18. Kanbur N.O., Derman O., Kutluk T., et al. Coagulation disorders as the cause of menorrhagia in adolescents. Int J Adolesc Med Health 2004, 16:183.
19. Mikhail S., Varadarajan R., Kouides P. The prevalence of disorders of haemostasis in adolescents with menorrhagia referred to a haemophilia treatment centre. Haemophilia 2007, 13:627.
20. Oral E., Cagdas A., Gezer A., et al. Hematological abnormalities in adolescent menorrhagia. Arch Gynecol Obstet 2002, 266:72.
21. Philipp C.S., Faiz A., Dowling N., et al. Age and the prevalence of bleeding disorders in women with menorrhagia. Obstet Gynecol 2005, 105:61.
22. Smith Y.R., Quint E.H., Hertzberg R.B. Menorrhagia in adolescents requiring hospitalization. J Pediatr Adolesc Gynecol 1998, 11:13.
23. Tosetto A., Rodeghiero F., Castaman G., et al. A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD). J Thromb Haemost 2006, 4:766.
24. Rodeghiero F., Castaman G., Tosetto A., et al. The discriminant power of bleeding history for the diagnosis of type 1 von Willebrand disease: an international, multicenter study. J Thromb Haemost 2005, 3:2619.
25. Woods A.I., Meschengieser S.S., Blanco A.N., et al. Clinical features and laboratory patterns in a cohort of consecutive Argentinian patients with von Willebrand's disease. Haematologica 2001, 86:420.
26. Mauser Bunschoten E.P., van Houwelingen J.C., Sjamsoedin Visser E.J., et al. Bleeding symptoms in carriers of hemophilia A and B. Thromb Haemost 1988, 59:349.
27. Sramek A., Eikenboom J.C., Briet E., et al. Usefulness of patient interview in bleeding disorders. Arch Intern Med 1995, 155:1409.
28. Nosek-Cenkowska B., Cheang M.S., Pizzi N.J., et al. Bleeding/bruising symptomatology in children with and without bleeding disorders. Thromb Haemost 1991, 65:237.
29. Bowman M., Mundell G., Grabell J., et al. Generation and validation of the Condensed MCMDM-1VWD Bleeding Questionnaire for von Willebrand disease. J Thromb Haemost 2008, 6:2062.
30. Bowman M., Riddel J., Rand M.L., et al. Evaluation of the diagnostic utility for von Willebrand disease of a pediatric bleeding questionnaire. J Thromb Haemost 2009, 7:1418.
31. Biss T.T., Blanchette V.S., Clark D.S., et al. Quantitation of bleeding symptoms in children with von Willebrand disease: use of a standardized pediatric bleeding questionnaire. J Thromb Haemost 2010, 8:950.
32. Abildgaard C.F., Suzuki Z., Harrison J., et al. Serial studies in von Willebrand's disease: variability versus ' variants. Blood 1980, 56:712.
33. Nichols W.L., Hultin M.B., James A.H., et al. von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia 2008, 14:171.
34. James A.H., Kouides P.A., Abdul-Kadir R., et al. Von Willebrand disease and other bleeding disorders in women: consensus on diagnosis and management from an international expert panel. Am J Obstet Gynecol 2009, 201:12.e1.
35. Kadir R.A., Economides D.L., Sabin C.A., et al. Variations in coagulation factors in women: effects of age, ethnicity, menstrual cycle and combined oral contraceptive. Thromb Haemost 1999, 82:1456.
36. Mandalaki T., Louizou C., Dimitriadou C., et al. Variations in factor VIII during the menstrual cycle in normal women. N Engl J Med 1980, 302:1093.
37. Miller C.H., Dilley A.B., Drews C., et al. Changes in von Willebrand factor and factor VIII levels during the menstrual cycle. Thromb Haemost 2002, 87:1082.
38. Bohm M., Taschner S., Kretzschmar E., et al. Cold storage of citrated whole blood induces drastic time-dependent losses in factor VIII and von Willebrand factor: potential for misdiagnosis of haemophilia and von Willebrand disease. Blood Coagul Fibrinolysis 2006, 17:39.
39. Lipton R.A. Misdiagnosis by milk box. Haemophilia 2003, 9:235.
40. Sadler J.E., Budde U., Eikenboom J.C., et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost 2006, 4:2103.
41. James P.D., Paterson A.D., Notley C., et al. Genetic linkage and association analysis in type 1 von Willebrand disease: results from the Canadian type 1 VWD study. J Thromb Haemost 2006, 4:783.
42. Eikenboom J., Van Marion V., Putter H., et al. Linkage analysis in families diagnosed with type 1 von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 VWD. J Thromb Haemost 2006, 4:774.
43. Lethagen S., Hillarp A., Ekholm C., et al. Distribution of von Willebrand factor levels in young women with and without bleeding symptoms: influence of ABO blood group and promoter haplotypes. Thromb Haemost 2008, 99:1013.
44. Gill J.C., Endres-Brooks J., Bauer P.J., et al. The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood 1987, 69:1691.
45. Sidonio R.F., Smith K.J., Ragni M.V. Cost-utility analysis of von Willebrand disease screening in adolescents with menorrhagia. J Pediatr 2010 Sep, 157(3):456-460. 460.e1. Epub 2010 May 6.
46. Rodeghiero F., Castaman G., Tosetto A. How I treat von Willebrand disease. Blood 2009, 114:1158.
47. Federici A.B., Mannucci P.M. Management of inherited von Willebrand disease in 2007. Ann Med 2007, 39:346.
48. Franchini M. The use of desmopressin as a hemostatic agent: a concise review. Am J Hematol 2007, 82:731.
49. Rainsford S.G., Jouhar A.J., Hall A. Tranexamic acid in the control of spontaneous bleeding in severe haemophilia. Thromb Diath Haemorrh 1973, 30:272.
50. Fraser I.S., Porte R.J., Kouides P.A., et al. A benefit-risk review of systemic haemostatic agents: part 2: in excessive or heavy menstrual bleeding. Drug Saf 2008, 31:275.
51. Rodeghiero F., Castaman G., Mannucci P.M. Prospective multicenter study on subcutaneous concentrated desmopressin for home treatment of patients with von Willebrand disease and mild or moderate hemophilia A. Thromb Haemost 1996, 76:692.
52. Bertholini D.M., Butler C.S. Severe hyponatraemia secondary to desmopressin therapy in von Willebrand's disease. Anaesth Intensive Care 2000, 28:199.
53. Kavanagh G.M., Sansom J.E., Harrison P., et al. Tranexamic acid (Cyklokapron)-induced fixed-drug eruption. Br J Dermatol 1993, 128:229.
54. Lucas-Polomeni M.M., Delaval Y., Menestret P., et al. A case of anaphylactic shock with tranexamique acid (Exacyl). Ann Fr Anesth Reanim 2004, 23:607.
55. Mannucci P.M., Lusher J.M. Desmopressin and thrombosis. Lancet 1989, 2(8664):675.
56. Byrnes J.J., Larcada A., Moake J.L. Thrombosis following desmopressin for uremic bleeding. Am J Hematol 1988, 28:63.
57. Grainge C., Nokes T. Cerebral arterial thrombosis in a young woman following vasopressin for von Willebrand's disease. Thromb Haemost 2005, 93:380.
58. Woo K.S., Tse L.K., Woo J.L., et al. Massive pulmonary thromboembolism after tranexamic acid antifibrinolytic therapy. Br J Clin Pract 1989, 43:465.
59. Taparia M., Cordingley F.T., Leahy M.F. Pulmonary embolism associated with tranexamic acid in severe acquired haemophilia. Eur J Haematol 2002, 68:307.
60. Lindoff C., Rybo G., Astedt B. Treatment with tranexamic acid during pregnancy, and the risk of thrombo-embolic complications. Thromb Haemost 1993, 70:238.
61. Berntorp E., Follrud C., Lethagen S. No increased risk of venous thrombosis in women taking tranexamic acid. Thromb Haemost 2001, 86:714.
62. Kadir R.A., Lee C.A., Sabin C.A., et al. DDAVP nasal spray for treatment of menorrhagia in women with inherited bleeding disorders: a randomized placebo-controlled crossover study. Haemophilia 2002, 8:787.
63. Leissinger C., Becton D., Cornell C., et al. High-dose DDAVP intranasal spray (Stimate) for the prevention and treatment of bleeding in patients with mild haemophilia A, mild or moderate type 1 von Willebrand disease and symptomatic carriers of haemophilia A. Haemophilia 2001, 7:258.
64. Mannucci P.M. Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years. Blood 1997, 90:2515.
65. Mannucci P.M., Canciani M.T., Rota L., et al. Response of factor VIII/von Willebrand factor to DDAVP in healthy subjects and patients with haemophilia A and von Willebrand's disease. Br J Haematol 1981, 47:283.
66. Rodeghiero F., Castaman G., Di Bona E., et al. Consistency of responses to repeated DDAVP infusions in patients with von Willebrand's disease and hemophilia A. Blood 1989, 74:1997.
67. Rose S.S., Faiz A., Miller C.H., et al. Laboratory response to intranasal desmopressin in women with menorrhagia and platelet dysfunction. Haemophilia 2008, 14:571.
68. Dunn A.L., Powers J.R., Ribeiro M.J., et al. Adverse events during use of intranasal desmopressin acetate for haemophilia A and von Willebrand disease: a case report and review of 40 patients. Haemophilia 2000, 6:11.
69. Amesse L.S., Pfaff-Amesse T., Leonardi R., et al. Oral contraceptives and DDAVP nasal spray: patterns of use in managing vWD-associated menorrhagia: a single-institution study. J Pediatr Hematol Oncol 2005, 27:357.
70. Mannucci P.M. Hemostatic drugs. N Engl J Med 1998, 339:245.
71. Kouides P.A., Byams V.R., Philipp C.S., et al. Multisite management study of menorrhagia with abnormal laboratory haemostasis: a prospective crossover study of intranasal desmopressin and oral tranexamic acid. Br J Haematol 2009, 145:212.
72. Tranexamic acid (Lysteda) for treatment of menorrhagia. Med Lett Drugs Ther 2010, 52(1342):54.
73. Siegbahn A., Odlind V., Hedner U., et al. Coagulation and fibrinolysis during the normal menstrual cycle. Ups J Med Sci 1989, 942:137.
74. Foster P.A. The reproductive health of women with von Willebrand Disease unresponsive to DDAVP: results of an international survey. On behalf of the Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the ISTH. Thromb Haemost 1995, 74:784.
75. Berntorp E., Petrini P. Long-term prophylaxis in von Willebrand disease. Blood Coagul Fibrinolysis 2005, (16 Suppl 1):S23.
76. Berntorp E., Abshire T. von Willebrand Disease Prophylaxis Network Steering Committee. The von Willebrand disease prophylaxis network: exploring a treatment concept. J Thromb Haemost 2006, 4:2511.
77. Goudemand J., Scharrer I., Berntorp E., et al. Pharmacokinetic studies on Wilfactin, a von Willebrand factor concentrate with a low factor VIII content treated with three virus-inactivation/removal methods. J Thromb Haemost 2005, 3:2219.
78. Borel-Derlon A., Federici A.B., Roussel-Robert V., et al. Treatment of severe von Willebrand disease with a high-purity von Willebrand factor concentrate (Wilfactin): a prospective study of 50 patients. J Thromb Haemost 2007, 5:1115.
79. Mannucci P.M., Franchini M., Castaman G., et al. Italian Association of Hemophilia Centers: Evidence-based recommendations on the treatment of von Willebrand disease in Italy. Blood Transfus 2009, 7:117.
80. Mannucci P.M., Moia M., Rebulla P., et al. Correction of the bleeding time in treated patients with severe von Willebrand disease is not solely dependent on the normal multimeric structure of plasma von Willebrand factor. Am J Hematol 1987, 25:55.
81. Castillo R., Monteagudo J., Escolar G., et al. Hemostatic effect of normal platelet transfusion in severe von Willebrand disease patients. Blood 1991, 77:1901.